Assessment of Prevalence of Low Testosterone Level in Men with Type 2 Diabetes Mellitus in Western U.P
DOI:
https://doi.org/10.21276/m7992t14Keywords:
Hypogonadism, Testosterone, Diabetes mellitusAbstract
Background: Diabetes Mellitus is a chronic disease that occurs either due to inadequate production of insulin or resistance to insulin action and excessive or inadequate production of glucagon. Hyperglycemia is a result of uncontrolled diabetes and over the time leads to damage to various body systems by microvascular, macrovascular and neuropathic complications. It is also seen that testosterone level was found low in uncontrolled type 2 diabetic patient.
Aim and objectives: To study the prevalence of low testosterone level in men with type 2 Diabetes mellitus and to study the prevalence of erectile dysfunction in men with type 2 Diabetes mellitus and its effect on daily activities of life.
Methods: This study was carried out in affiliated hospital of Saraswathi institute of medical sciences, Hapur in the Department of Medicine. 100 males of type 2 Diabetes Mellitus were selected to see the prevalence of low level of testosterone. Results: 100 type 2 DM patients with age above 40years were enrolled in this study to look for serum testosterone level. In 69 patients in whom HbA1C was more than 7.5% testosterone level was found low. Erectile dysfunction was observed in low testosterone groups. Association between type2 DM and hypogonadism has been studied in detail in various studies also but whether treatment of DM can treat hypogonadism or testosterone can improve glycaemic control in Diabetic patients with hypogonadism is still controversial.
Conclusions: The high prevalence of both low testosterone levels and of ED should prompt the screening of all diabetic male patients older than 40 years.
Downloads
References
Aboelnaga MM et al.Prevalence and predictors for low total testosterone levels among male type 2 diabetic patients: an Egyptian experience. Int J Res Med Sci. 2016;4(8):3381-3387.
Agbecha A, Usoro CA. Serum testosterone and insulin resistance in type 2 male diabetics attending University of Calabarteaching hospital, Nigeria. J Med Soc. 2017;31:178-84.
Chaudhary S, Kaushik M, Jaswal VMS, Raina R, Thakur R, Thakur MK, et al. Testosterone levels in men with type 2 diabetes mellitus. Int J Res Med Sci 2018;6:2313-7.
Geoffrey Hackett: T2DM and Testosterone Therapy.World J Mens Health 2019 January 37(1): 31-44.
Zheng R, Cao L Wen, Cao W, Chu X, et al.Risk Factors for Hypogonadism in Male Patients with Type 2 Diabetes.Journal of Diabetes Research.2016;1(1):1-8
Madhu SV, Aslam M, Aiman AJ, Siddiqui A, Dwivedi S. Prevalence of hypogonadism in male Type 2 diabetes mellitus patients with and without coronary artery disease. Indian J EndocrMetab 2017;21:31-7.
Karakas M, Schäfer S, Appelbaum S , Ojeda F, KuulasmaaK.Testosterone Levels and Type 2 Diabetes—No Correlation with Age, Differential Predictive Value in Men and Women.Biomolecules2018;8(3):76-80
Trivedi J, Kapoor S. A Study of Serum Total Testosterone Levels in Type 2 Diabetes Mellitus Male Patients. Ann. Int. Med. Den. Res. 2017; 3(4):01-05.
Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR, Baltimore Longitudinal Study of Aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.JClinEndocrinolMetab. 2001; 86(2):724-31.
Daniell HW. Hypogonadism in men consuming sustained-action oral opioids.J Pain.2002 ; 3(5):377-84.
Cumming DC, Quigley ME, Yen SS Acute suppression of circulating testosterone levels by cortisol in men.JClinEndocrinolMetab. 1983 Sep; 57(3):671-3.
Tajar A, Huhtaniemi IT, O‟Neill TW, et al. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J ClinEndocrinolMetab 2012; 97:1508-1516.
Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J linEndocrinolMetab 2010; 95:2536-2559.
Wu FC, Tajar A, Pye SR, et al. Hypothalamic-pituitary-testicular axis disruptions in oldermen are differentially linked to age and modifiable risk factors: the European Male Aging Study. J ClinEndocrinolMetab 2008; 93:2737-2745.
Travison TG, Araujo AB, Kupelian V, et al. The relative contributions of aging, health,and lifestyle factors to serum testosterone decline in men. J ClinEndocrinolMetab 2007;92:549-555.
Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J ClinEndocrinolMetab 2001; 86:724-731.
Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J ClinEndocrinolMetab 2007; 92:4241-4247.
Wu FCW, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadismin middle-aged and elderly men. N Engl J Med 2010; 363:123-35.
Swerdloff R, Wang C. Testosterone treatment of older men- Why are controversiescreated? J ClinEndocrinolMetab 2011; 91(1):62-65.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 International Archives of BioMedical and Clinical Research
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors are required to sign and submit the completed “Copyright transfer Form” upon acceptance of publication of the paper. This is determined by a publishing agreement between the author and International Archives of Biomedical and Clinical Research. These rights might include the right to publish, communicate and distribute online. Author(s) retain the copyright of their work. International Archives of Biomedical and Clinical Research supports the need for authors to share, disseminate and maximize the impact of their research.
